Key Highlights

  • Thermo Fisher Scientific (NYSE:TMO) reported adjusted EPS of USD 6.68 on Wednesday, October 21, 2026, against a USD 6.40 consensus, on 6% organic growth, with margins wider in all four segments and Analytical Instruments at 26.9%.
  • Danaher (NYSE:DHR) beat with adjusted diluted EPS of USD 2.11 against USD 1.92 on core growth of 3.0%, while acquisitions added 16.5 points to Diagnostics sales and full-year guidance rose to USD 8.57 to USD 8.62.
  • Medpace (NASDAQ:MEDP) earned diluted EPS of USD 4.84 against a USD 4.46 consensus, booked net awards of USD 873.4 million, about 1.22 times revenue by simple arithmetic, and approved a USD 1.0 billion buyback.
  • Integra LifeSciences (NASDAQ:IART) earned adjusted EPS of USD 0.59 against a USD 0.56 consensus on 2.5% organic growth and completed a USD 2.1 billion refinancing that includes USD 450 million of 9.5% senior secured notes.

Thermo Fisher Scientific (NYSE:TMO): operating leverage in every segment

Thermo Fisher Scientific (NYSE:TMO), the Waltham, Massachusetts supplier of laboratory instruments, consumables and drug development services, reported before the open on Wednesday, October 21, 2026. Revenue rose 9% to USD 12.14 billion, with organic growth of 6%. Adjusted EPS rose 15% to USD 6.68, above the consensus estimate of USD 6.40, and adjusted operating margin widened to 24.5% from 23.3%. Analytical Instruments posted a 26.9% segment margin, up from 22.6%, on revenue up about 6% to USD 2.00 billion, and Specialty Diagnostics reached 31.0% from 27.4% even as its revenue fell to USD 1.10 billion in the quarter the microbiology sale closed.

The mechanism is operating leverage, profit rising faster than sales: the instrument margin gained 4.3 points on revenue growth of about 6%, although the release does not break out the drivers. Over nine months, free cash flow rose 39% to USD 4.62 billion, funding USD 4.0 billion of buybacks alongside USD 8.88 billion of acquisitions. The risks are cyclical instrument demand, since equipment purchases depend on customer budgets and can be deferred, and integration, with restructuring and other costs of USD 199 million in the quarter. GAAP diluted EPS of USD 4.64 shows the gap those charges leave.

Danaher (NYSE:DHR): acquired growth and a tax benefit

Danaher (NYSE:DHR), the Washington, D.C. based life sciences and diagnostics group, reported third-quarter results on Wednesday, October 21, 2026. Revenue rose 8.5% to USD 6.55 billion, but core growth, which strips out acquisitions and currency, was 3.0%, at the top of the 2% to 3% range flagged before results, and 5.5% excluding respiratory testing. Diagnostics sales rose 17.0%, with acquisitions contributing 16.5 points and core growth of 0.5%. Adjusted diluted EPS was USD 2.11, against the consensus estimate of USD 1.92, and full-year adjusted EPS guidance rose to USD 8.57 to USD 8.62 from USD 8.45 to USD 8.60.

Here capital shows up as acquired revenue. The release ties USD 84 million of inventory fair value adjustments to Masimo, the patient monitoring company, and Danaher excludes these from adjusted EPS along with USD 513 million of amortisation. GAAP diluted EPS from continuing operations rose to USD 1.71 from USD 1.27, helped by a discrete tax benefit of USD 263 million, or USD 0.37 per share. The risks are respiratory testing, guided as a headwind of about 150 basis points in the fourth quarter, and rates, which weigh on biotechnology customers with the federal funds range at 3.75% to 4.00%.

Medpace (NASDAQ:MEDP): orders ahead of revenue and a larger buyback

Medpace (NASDAQ:MEDP), the Cincinnati-based contract research organisation that runs clinical trials for drug developers, reported third-quarter results after the close on Wednesday, October 21, 2026. Revenue rose 8.5% to USD 716.0 million, while net new business awards, the value of contracts signed minus cancellations, rose 10.6% to USD 873.4 million. Backlog rose 5.6% to USD 3.17 billion. EBITDA rose 16.0% to USD 172.1 million at a 24.0% margin, up from 22.5%, and diluted EPS, which Medpace reports on a GAAP basis only, was USD 4.84 against the consensus estimate of USD 4.46.

Book-to-bill, awards divided by revenue, was about 1.22, calculated from published figures, so the quarter added roughly USD 157 million more in awards than it recognised as revenue. Backlog converts at a rate the release puts at 23.8% a quarter. Capital is the other lever: the board ended the prior buyback programme, which had USD 527.0 million left, and approved up to USD 1.0 billion through December 31, 2028. That exceeds cash of USD 705.3 million, so full use would draw on future cash flow. The risk is client funding, since smaller biotechnology sponsors depend on capital markets.

Integra LifeSciences (NASDAQ:IART): paying 9.5% for covenant headroom

Integra LifeSciences (NASDAQ:IART), the Princeton, New Jersey maker of neurosurgery products, surgical instruments and tissue repair products, reported third-quarter results at 6:00 a.m. ET on Wednesday, October 21, 2026. Revenue rose 2.3% to USD 411.2 million, or 2.5% organically, after a Cincinnati flood cost about USD 7 million of sales. Specialty Surgery grew 4.2% organically, led by Neuro at 6.5%, while Tissue Reconstruction fell 2.2%. Adjusted EPS was USD 0.59, against the consensus estimate of USD 0.56 and within the USD 0.53 to USD 0.61 guidance flagged before results, while adjusted gross margin eased to 61.1% from 62.9%.

Integra sits at the other end of the capital spectrum: rather than returning cash, it refinanced. The USD 2.1 billion package completed on Monday, October 19, 2026 includes a USD 1.65 billion senior secured credit facility and USD 450 million of 9.5% senior secured notes due 2033, and the company expects its effective interest rate to rise near the high end of a 100 to 200 basis point range. In return, the maximum permitted net leverage was raised temporarily, with a step-down to 4.25 times during 2027, against leverage of 3.8 times. Free cash flow rose to USD 85.7 million from USD 25.8 million. The risks are interest cost, covenant headroom and the SurgiMend relaunch planned for the fourth quarter.

Where Things Stand

The answer is that reported revenue growth stayed in single digits at all four, from 2.3% at Integra LifeSciences (NASDAQ:IART) to 9% at Thermo Fisher Scientific (NYSE:TMO), so margins and capital decided the beats. Thermo Fisher widened margins in every segment and bought back USD 4.0 billion of stock over nine months, Danaher (NYSE:DHR) added 16.5 points of acquired Diagnostics growth, and Medpace (NASDAQ:MEDP) signed more work than it delivered while setting a USD 1.0 billion buyback. Integra instead paid 9.5% on new notes for covenant headroom. The next catalysts are the Medpace call at 9:00 a.m. ET on Thursday, October 22, 2026, the Fed decision on Wednesday, October 28 and fourth-quarter results. Guidance and backlog are not guaranteed results, and this is not investment advice.